A multi-center randomised controlled trial of gatifloxacin versus azithromycin for the treatment of uncomplicated typhoid fever in children and adults in Vietnam

Christiane Dolecek, Thi Phi La Tran, Ngoc Rang Nguyen, Thi Phuong Le, Vinh Ha, Quoc Tuan Phung, Cong Du Doan, Thi Be Bay Nguyen, Thanh Long Duong, Bich Ha Luong, Trung Binh Nguyen, Thi Anh Hong Nguyen, Ngoc Dung Pham, Ngoc Lanh Mai, Van Be Bay Phan, Anh Ho Vo, Van Minh Hoang Nguyen, Thu Thi Nga Tran, Thuy Chau Tran, Constance Schultsz, Sarah J Dunstan, Kasia Stepniewska, James Ian Campbell, Song Diep To, Buddha Basnyat, Van Vinh Chau Nguyen, Van Sach Nguyen, Tran Chinh Nguyen, Tinh Hien Tran, Jeremy Farrar, Christiane Dolecek, Thi Phi La Tran, Ngoc Rang Nguyen, Thi Phuong Le, Vinh Ha, Quoc Tuan Phung, Cong Du Doan, Thi Be Bay Nguyen, Thanh Long Duong, Bich Ha Luong, Trung Binh Nguyen, Thi Anh Hong Nguyen, Ngoc Dung Pham, Ngoc Lanh Mai, Van Be Bay Phan, Anh Ho Vo, Van Minh Hoang Nguyen, Thu Thi Nga Tran, Thuy Chau Tran, Constance Schultsz, Sarah J Dunstan, Kasia Stepniewska, James Ian Campbell, Song Diep To, Buddha Basnyat, Van Vinh Chau Nguyen, Van Sach Nguyen, Tran Chinh Nguyen, Tinh Hien Tran, Jeremy Farrar

Abstract

Background: Drug resistant typhoid fever is a major clinical problem globally. Many of the first line antibiotics, including the older generation fluoroquinolones, ciprofloxacin and ofloxacin, are failing.

Objectives: We performed a randomised controlled trial to compare the efficacy and safety of gatifloxacin (10 mg/kg/day) versus azithromycin (20 mg/kg/day) as a once daily oral dose for 7 days for the treatment of uncomplicated typhoid fever in children and adults in Vietnam.

Methods: An open-label multi-centre randomised trial with pre-specified per protocol analysis and intention to treat analysis was conducted. The primary outcome was fever clearance time, the secondary outcome was overall treatment failure (clinical or microbiological failure, development of typhoid fever-related complications, relapse or faecal carriage of S. typhi).

Principal findings: We enrolled 358 children and adults with suspected typhoid fever. There was no death in the study. 287 patients had blood culture confirmed typhoid fever, 145 patients received gatifloxacin and 142 patients received azithromycin. The median FCT was 106 hours in both treatment arms (95% Confidence Interval [CI]; 94-118 hours for gatifloxacin versus 88-112 hours for azithromycin), (logrank test p = 0.984, HR [95% CI] = 1.0 [0.80-1.26]). Overall treatment failure occurred in 13/145 (9%) patients in the gatifloxacin group and 13/140 (9.3%) patients in the azithromycin group, (logrank test p = 0.854, HR [95% CI] = 0.93 [0.43-2.0]). 96% (254/263) of the Salmonella enterica serovar Typhi isolates were resistant to nalidixic acid and 58% (153/263) were multidrug resistant.

Conclusions: Both antibiotics showed an excellent efficacy and safety profile. Both gatifloxacin and azithromycin can be recommended for the treatment of typhoid fever particularly in regions with high rates of multidrug and nalidixic acid resistance. The cost of a 7-day treatment course of gatifloxacin is approximately one third of the cost of azithromycin in Vietnam.

Trial registration: Controlled-Trials.com ISRCTN67946944.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Profile of the Trial.
Figure 1. Profile of the Trial.
Figure 2. Proportion of culture confirmed patients…
Figure 2. Proportion of culture confirmed patients still febrile.
Kaplan-Meier survival curve showing the proportion of culture confirmed patients (PP analysis) still febrile through time by treatment group.
Figure 3. Proportion of all randomised patients…
Figure 3. Proportion of all randomised patients still febrile.
Kaplan-Meier survival curve showing the proportion of all randomised patients (ITT analysis) still febrile through time by treatment group.
Figure 4. Proportion of patients with overall…
Figure 4. Proportion of patients with overall failure in the culture confirmed population.
Kaplan-Meier survival curve showing the proportion of patients with overall failure in the culture confirmed population (PP analysis) by treatment group.
Figure 5. Proportion of patients with relapse…
Figure 5. Proportion of patients with relapse in the culture confirmed population.
Kaplan-Meier survival curve showing the proportion of patients with relapse in the culture confirmed population (PP analysis) by treatment group.

References

    1. Crump JA, Luby SP, Mintz ED. The global burden of typhoid fever. Bull World Health Organ. 2004;82:346–353.
    1. Bhan MK, Bahl R, Bhatnagar S. Typhoid and paratyphoid fever. Lancet. 2005;366:749–762.
    1. Bhutta ZA. Current concepts in the diagnosis and treatment of typhoid fever. Bmj. 2006;333:78–82.
    1. Parry CM, Hien TT, Dougan G, White NJ, Farrar JJ. Typhoid fever. N Engl J Med. 2002;347:1770–1782.
    1. Nguyen TA, Ha Ba K, Nguyen TD. [Typhoid fever in South Vietnam, 1990–1993]. Bull Soc Pathol Exot. 1993;86:476–478.
    1. Chau TT, Campbell JI, Galindo CM, Van Minh Hoang N, Diep TS, et al. Antimicrobial drug resistance of Salmonella enterica serovar Typhi in Asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. Antimicrob Agents Chemother. 2007;51:4315–4323.
    1. Chinh NT, Parry CM, Ly NT, Ha HD, Thong MX, et al. A randomized controlled comparison of azithromycin and ofloxacin for treatment of multidrug-resistant or nalidixic acid-resistant enteric fever. Antimicrob Agents Chemother. 2000;44:1855–1859.
    1. Parry CM, Ho VA, Phuong le T, Bay PV, Lanh MN, et al. Randomized controlled comparison of ofloxacin, azithromycin, and an ofloxacin-azithromycin combination for treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever. Antimicrob Agents Chemother. 2007;51:819–825.
    1. WHO. Backgound document: The diagnosis, treatment and prevention of typhoid fever. Department of Vaccines and Biologicals - World Health Organization. 2003 .
    1. Pandit A, Arjyal A, Day JN, Paudyal B, Dangol S, et al. An open randomized comparison of gatifloxacin versus cefixime for the treatment of uncomplicated enteric fever. PLoS ONE. 2007;2:e542.
    1. Maskey AP, Day JN, Phung QT, Thwaites GE, Campbell JI, et al. Salmonella enterica serovar Paratyphi A and S. enterica serovar Typhi cause indistinguishable clinical syndromes in Kathmandu, Nepal. Clin Infect Dis. 2006;42:1247–1253.
    1. Clinical and Laboratory Standard Institute. Performance standards for antimicrobial susceptibility tests. Approved standard, 9th ed. CLSI document M2-A9. 2006 CLSI, Pennsylvania, USA.
    1. Clinical and Laboratory Standard Institute. Performance standards for antimicrobial susceptibility testing; seventeenth informational supplement. MS100-S17. 2007 CLSI, Pennsylvania, USA.
    1. Machin D, Campbell MJ, Fayers PM, Pinol APY. Sample size tables for the design of clinical trials (2nd edition) Oxford: Blackwell Science; 1997.
    1. Breslow NE, Day NE. Statistical methods in cancer research. Volume 1 - The analysis of case-control studies. Lyon: International Agency for Research on Cancer; 1980.
    1. Collett D. Modelling survival data in medical research (2nd edition) Boca Raton: CRC Press; 2003.
    1. Cao XT, Kneen R, Nguyen TA, Truong DL, White NJ, et al. A comparative study of ofloxacin and cefixime for treatment of typhoid fever in children. The Dong Nai Pediatric Center Typhoid Study Group. Pediatr Infect Dis J. 1999;18:245–248.
    1. Tran TH, Bethell DB, Nguyen TT, Wain J, To SD, et al. Short course of ofloxacin for treatment of multidrug-resistant typhoid. Clin Infect Dis. 1995;20:917–923.
    1. Vinh H, Wain J, Vo TN, Cao NN, Mai TC, et al. Two or three days of ofloxacin treatment for uncomplicated multidrug-resistant typhoid fever in children. Antimicrob Agents Chemother. 1996;40:958–961.
    1. Lu T, Zhao X, Drlica K. Gatifloxacin activity against quinolone-resistant gyrase: allele-specific enhancement of bacteriostatic and bactericidal activities by the C-8-methoxy group. Antimicrob Agents Chemother. 1999;43:2969–2974.
    1. Tam VH, Louie A, Deziel MR, Liu W, Drusano GL. The relationship between quinolone exposures and resistance amplification is characterized by an inverted U: a new paradigm for optimizing pharmacodynamics to counterselect resistance. Antimicrob Agents Chemother. 2007;51:744–747.
    1. Ambrose PG, Bhavnani SM, Cirincione BB, Piedmonte M, Grasela TH. Gatifloxacin and the elderly: pharmacokinetic-pharmacodynamic rationale for a potential age-related dose reduction. J Antimicrob Chemother. 2003;52:435–440.
    1. Baker SE, Hangii MC. Possible gatifloxacin-induced hypoglycemia. Ann Pharmacother. 2002;36:1722–1726.
    1. Frothingham R. Glucose homeostasis abnormalities associated with use of gatifloxacin. Clin Infect Dis. 2005;41:1269–1276.
    1. Park-Wyllie LY, Juurlink DN, Kopp A, Shah BR, Stukel TA, et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med. 2006;354:1352–1361.
    1. Pichichero ME, Arguedas A, Dagan R, Sher L, Saez-Llorens X, et al. Safety and efficacy of gatifloxacin therapy for children with recurrent acute otitis media (AOM) and/or AOM treatment failure. Clin Infect Dis. 2005;41:470–478.
    1. Aarestrup FM, Wiuff C, Molbak K, Threlfall EJ. Is it time to change fluoroquinolone breakpoints for Salmonella spp.? Antimicrob Agents Chemother. 2003;47:827–829.
    1. Kadhiravan T, Wig N, Kapil A, Kabra SK, Renuka K, et al. Clinical outcomes in typhoid fever: adverse impact of infection with nalidixic acid-resistant Salmonella typhi. BMC Infect Dis. 2005;5:37.
    1. Thaver D, Zaidi AK, Critchley J, Madni SA, Bhutta ZA. Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever). Cochrane Database Syst Rev. 2005:CD004530.
    1. Frenck RW, Jr, Mansour A, Nakhla I, Sultan Y, Putnam S, et al. Short-course azithromycin for the treatment of uncomplicated typhoid fever in children and adolescents. Clin Infect Dis. 2004;38:951–957.
    1. Butler T, Sridhar CB, Daga MK, Pathak K, Pandit RB, et al. Treatment of typhoid fever with azithromycin versus chloramphenicol in a randomized multicentre trial in India. J Antimicrob Chemother. 1999;44:243–250.
    1. Frenck RW, Jr, Nakhla I, Sultan Y, Bassily SB, Girgis YF, et al. Azithromycin versus ceftriaxone for the treatment of uncomplicated typhoid fever in children. Clin Infect Dis. 2000;31:1134–1138.
    1. Girgis NI, Butler T, Frenck RW, Sultan Y, Brown FM, et al. Azithromycin versus ciprofloxacin for treatment of uncomplicated typhoid fever in a randomized trial in Egypt that included patients with multidrug resistance. Antimicrob Agents Chemother. 1999;43:1441–1444.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する